{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:59:42Z","timestamp":1792789182757,"version":"4.5.0"},"reference-count":85,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Russian Science Foundation","award":["#25-15-00086"],"award-info":[{"award-number":["#25-15-00086"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"crossref"}]},{"award":["#25-15-00086"],"award-info":[{"award-number":["#25-15-00086"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Overexpression and increased activity of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (ABCB1\/P-gp), breast cancer resistance protein (ABCG2\/BCRP), and multidrug resistance-associated proteins (ABCC\/MRPs), are known to be among the major contributors to multidrug resistance (MDR) in tumors to structurally similar or even different chemotherapeutic agents, thereby decreasing treatment efficacy. Thus, there is an urgent need to develop novel, effective therapies that overcome MDR and increase chemotherapy response rates. Results: We showed here that receptor tyrosine kinase inhibitors (RTKIs) designed to inhibit the overactivated FGFR and\/or VEGFR signaling pathways exert an \u201coff-target\u201d effect on MDR proteins in colorectal cancer (CRC), thereby sensitizing CRC to certain chemotherapies. In particular, Pemigatinib and Infigratinib ranked among the top eight tested selective and non-selective FGFR\/VEGFR inhibitors that effectively resensitized all types of CRCs to the DNA topoisomerase II inhibitor Doxorubicin and, in fewer experimental settings, to the antimetabolite 5-Fluorouracil. This was evidenced by a significant increase in apoptosis in CRCs treated with the aforementioned chemotherapeutic drugs in combination with RTKIs. Of note, despite the CRCs exhibiting signs of FGFR and VEGFR activation, RTKIs alone exhibited only minor pro-apoptotic and anti-proliferative activities. The enhancement of pro-apoptotic activity of Doxorubicin when co-treated with Pemigatinib, Lucitanib, and Regorafenib in HCT116 cells was consistent with a decrease in proliferative activity in CRCs treated with these RTKIs alone. This was also revealed by high synergy scores (SC) between several RTKIs (e.g., Pemigatinib, Lucitanib, and Regorafenib) and Doxorubicin in CRCs. The aforementioned effects of RTKIs were due to the inhibition of MDR-related ABC transporter activity, particularly ABCB1 and ABCG2. Indeed, in HCT116 cells, Lucitanib and, to a lesser extent, Pemigatinib impaired the efflux of the intrinsically fluorescent Doxorubicin and Mitoxantrone. Similarly, the efflux of Calcein AM, an ABCB1 substrate, was significantly impaired in Lucitanib- and Pemigatinib-treated CRCs, thereby revealing ABCB1 as a molecular target for these RTKIs. Consistent with SC data, Infigratinib and Cabozatinib effectively impaired the efflux of Doxorubicin from Colon-26 cells. Similarly, ABCB1 protein was found to be a primary target for Infigratinib in Colon-26 cancer cells, which was evidenced by competitive assay data based on the combined use of selective ABCB1 and ABCG2 inhibitors (e.g., Tariquidar and Ko-143, respectively). Importantly, ABC-inhibitory effects of RTKIs in CRCs were mediated solely by the impaired efflux of chemotherapeutic agents from CRCs and were not due to the decreased expression of ABC transporters or their subcellular distribution. Lastly, in the small-cohort allograft study, we found Infigratinib to be an effective chemosensitizing agent for the Colon-26 murine colon carcinoma in vivo. This was evidenced by the reduced growth of Colon-26 allografts in the experimental group receiving the combined therapy of Infigratinib and Doxorubicin compared with the single-treated groups. Consistent with these findings, immunohistochemical (IHC) staining revealed a substantial increase in apoptotic cells (e.g., cleaved caspase-3-positive) and a decrease in proliferative cells (e.g., Ki-67-positive) in allografts from animals treated with a combination of Infigratinib and Doxorubicin. Conclusions: We show here for the first time that some FGFR inhibitors (e.g., Pemigatinib and Infigratinib) can effectively potentiate cytotoxic and anti-proliferative activity against CRCs overexpressing MDR-related ABC transporters, thereby suggesting potential therapeutic avenues for treating CRC that progresses despite standard conventional therapies.<\/jats:p>","DOI":"10.3390\/cancers18193074","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:21:48Z","timestamp":1790072508000},"page":"3074","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2415-1084","authenticated-orcid":false,"given":"Sergei","family":"Boichuk","sequence":"first","affiliation":[{"name":"Department of Pathology, Kazan State Medical University, Kazan 420012, Russia"},{"name":"Department of Radiotherapy and Radiology, Russian Medical Academy of Continuous Professional Education, Moscow 125051, Russia"},{"name":"Central Research Laboratory, Kazan State Medical University, Kazan 420012, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4348-9141","authenticated-orcid":false,"given":"Tatyana","family":"Gessel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kazan State Medical University, Kazan 420012, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-4435","authenticated-orcid":false,"given":"Pavel","family":"Dunaev","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kazan State Medical University, Kazan 420012, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"software","vocabulary":"credit"}]},{"given":"Alina","family":"Galyautdinova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kazan State Medical University, Kazan 420012, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6210-4660","authenticated-orcid":false,"given":"Emiliya S.","family":"Egorova","sequence":"additional","affiliation":[{"name":"Central Research Laboratory, Kazan State Medical University, Kazan 420012, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-4274","authenticated-orcid":false,"given":"Pavel B.","family":"Kopnin","sequence":"additional","affiliation":[{"name":"Division of Translational Oncology, N.N. Blokhin National Medical Research Center of Oncology, Moscow 115478, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Andriutsa","sequence":"additional","affiliation":[{"name":"Department of Pathological Physiology, Sechenov First Moscow State Medical University, Moscow 119019, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-2974","authenticated-orcid":false,"given":"Aigul","family":"Galembikova","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kazan State Medical University, Kazan 420012, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today (Version 1.1), International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Alrushaid, N., Khan, F.A., Al-Suhaimi, E., and Elaissari, A. (2023). Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments. Diseases, 11.","DOI":"10.3390\/diseases11040148"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","first-page":"263","article-title":"Basic review of the cytochrome p450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0065-230X(05)94004-9","article-title":"Apoptotic Pathways and Therapy Resistance in Human Malignancies","volume":"94","author":"Viktorsson","year":"2005","journal-title":"Adv. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-Mesenchymal Transition Is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Du, B., and Shim, J.S. (2016). Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules, 21.","DOI":"10.3390\/molecules21070965"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","article-title":"Cancer stem cells: Advances in knowledge and implications for cancer therapy","volume":"9","author":"Chu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17650\/2313-805X-2024-11-1-8-21","article-title":"The role of ABC-transporters in homeostasis, cancer pathogenesis and therapy","volume":"11","author":"Boichuk","year":"2024","journal-title":"Adv. Mol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., and Khan, F.S. (2022). Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life, 12.","DOI":"10.3390\/life12060897"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-09-1321","article-title":"P-glycoprotein (P-gp\/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide","volume":"16","author":"Lagas","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","article-title":"Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_17","first-page":"249","article-title":"Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens","volume":"25","author":"Satake","year":"2015","journal-title":"Biomed. Mater. Eng."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_19","first-page":"287","article-title":"Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer","volume":"35","author":"Kovalev","year":"2013","journal-title":"Exp. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.leukres.2012.07.003","article-title":"Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells","volume":"36","author":"Tsubaki","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1080\/10428190600881421","article-title":"MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia","volume":"47","author":"Matthews","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.leukres.2004.06.004","article-title":"BCRP mRNA expression v. clinical outcome in 40 adult AML patients","volume":"29","author":"Uggla","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \u201cspecific\u201d P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1124\/jpet.115.225482","article-title":"The Inhibitor Ko143 Is Not Specific for ABCG2","volume":"354","author":"Weidner","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drup.2012.01.005","article-title":"Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance","volume":"15","author":"Shukla","year":"2012","journal-title":"Drug Resist. Updates"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Boichuk, S., and Gessel, T. (2025). Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review. Cancers, 17.","DOI":"10.3390\/cancers17203354"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2012.10.001","article-title":"Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models","volume":"328","author":"Tiwari","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26142","DOI":"10.18632\/oncotarget.4536","article-title":"Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Sims, J.T., Ganguly, S.S., Bennett, H., Friend, J.W., Tepe, J., and Plattner, R. (2013). Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-\u03baB and HSP27\/p38\/AKT pathways and by inhibiting ABCB1. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055509"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: Implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1158\/0008-5472.CAN-05-2915","article-title":"Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo","volume":"66","author":"Leggas","year":"2006","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2119\/molmed.2014.00059","article-title":"Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function","volume":"20","author":"Ma","year":"2014","journal-title":"Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1158\/0008-5472.CAN-07-2686","article-title":"Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2009.01.027","article-title":"Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2","volume":"279","author":"Dai","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1038\/emm.2016.168","article-title":"Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo","volume":"49","author":"Yang","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1111\/bph.12889","article-title":"In vitro, in vivo and ex vivo characterization of ibrutinib: A potent inhibitor of the efflux function of the transporter MRP1","volume":"171","author":"Zhang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/mol.111.076299","article-title":"Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo","volume":"82","author":"Zhao","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1535-7163.MCT-15-0939","article-title":"Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Boichuk, S., Dunaev, P., Mustafin, I., Mani, S., Syuzov, K., Valeeva, E., Bikinieva, F., and Galembikova, A. (2022). Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030601"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(03)13603-3","article-title":"Antiangiogenesis drug promising for metastatic colorectal cancer","volume":"361","author":"McCarthy","year":"2003","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"526178","DOI":"10.1155\/2014\/526178","article-title":"Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: Role of aflibercept","volume":"2014","author":"Giordano","year":"2014","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.7150\/jca.40531","article-title":"FGF\/FGFR signaling pathway involved in resistance in various cancer types","volume":"11","author":"Zhou","year":"2020","journal-title":"J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Dakowicz, D., Zajkowska, M., and Mroczko, B. (2022). Relationship between VEGF Family Members, Their Receptors and Cell Death in the Neoplastic Transformation of Colorectal Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063375"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Boichuk, S., Bikinieva, F., Valeeva, E., Dunaev, P., Vasileva, M., Kopnin, P., Mikheeva, E., Ivoilova, T., Mustafin, I., and Galembikova, A. (2023). Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline. Diagnostics, 13.","DOI":"10.3390\/diagnostics13162646"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.3892\/ol.2017.6795","article-title":"Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance","volume":"14","author":"Boichuk","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Boichuk, S., Galembikova, A., Dunaev, P., Valeeva, E., Shagimardanova, E., Gusev, O., and Khaiboullina, S. (2017). A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance. Molecules, 22.","DOI":"10.3390\/molecules22122152"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2468-1253(21)00220-X","article-title":"Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements","volume":"6","author":"Neuzillet","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: The PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO-26-00788","article-title":"Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial","volume":"44","author":"Melisi","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"EVI-Doa2500017","DOI":"10.1056\/EVIDoa2500017","article-title":"Pemigatinib for Myeloid\/Lymphoid Neoplasms with FGFR1 Rear-rangement","volume":"4","author":"Verstovsek","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10637-023-01340-z","article-title":"A phase 1b study of the allosteric extracellular FGFR2 inhibitor alo-fanib in patients with pretreated ad-vanced gastric cancer","volume":"41","author":"Tsimafeyeu","year":"2023","journal-title":"Invest. New Drugs."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"P6\u201311-03","DOI":"10.1158\/1538-7445.SABCS16-P6-11-03","article-title":"Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)","volume":"77","author":"Mayer","year":"2017","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/1078-0432.CCR-19-1164","article-title":"Lucitanib for the Treatment of HR+\/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study","volume":"26","author":"Hui","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-018-03765-3","article-title":"A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer","volume":"83","author":"Campone","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.2018.109","article-title":"Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma","volume":"5","author":"Vecchio","year":"2018","journal-title":"J. Kidney Cancer VHL."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-22-0873","article-title":"Cabozantinib for Differentiated Thyroid Cancer","volume":"28","author":"Duke","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1758834014544892","article-title":"Regorafenib in gastrointestinal stromal tumors: Clinical evidence and place in therapy","volume":"6","author":"Ferraro","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (COR-RECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/2159-8290.CD-NB2017-070","article-title":"Regorafenib Approved for Liver Cancer","volume":"7","author":"Roh","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Boichuk, S., Dunaev, P., Galembikova, A., and Valeeva, E. (2024). Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance. Cancers, 16.","DOI":"10.3390\/cancers16173103"},{"key":"ref_72","first-page":"9","article-title":"Lapatinib potentiates cytotoxic activity of doxorubicin in multidrug-resistant tumor cells in vitro","volume":"15","author":"Boichuk","year":"2024","journal-title":"Oncol. Bull. Volga Reg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.17650\/2313-805X-2025-12-4-109-124","article-title":"Over-expression of ABC transporters in gastrointestinal stromal tumors as one of the mecha-nisms for the development of second-ary chemoresistance","volume":"12","author":"Bikinieva","year":"2025","journal-title":"Adv. Mol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.vascn.2010.11.003","article-title":"Rapid detection of ABC transporter interaction: Po-tential utility in phar-macology","volume":"63","author":"Robey","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Siedlecka-Kroplewska, K., Wro\u0144ska, A., and Kmie\u0107, Z. (2021). Piceatannol, a Structural Analog of Resveratrol, Is an Apoptosis Inducer and a Multidrug Resistance Modulator in HL-60 Human Acute Myeloid Leukemia Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910597"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1124\/dmd.113.053140","article-title":"Overlapping substrate and inhibitor specificity of human and murine ABCG2","volume":"41","author":"Bakhsheshian","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Moosavi, F., Hassani, B., Mortazavi, M., Peters, G.J., and Firuzi, O. (2026). Protein Kinase Inhibitors as Regulators of ABC Transporters in Overcoming Cancer Multidrug Resistance: A Comprehensive Review of Recent Ad-vances. Cancers, 18.","DOI":"10.3390\/cancers18121957"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1470-2045(21)00199-6","article-title":"Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: An international population-based study","volume":"22","author":"Cardoso","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/j.seminoncol.2011.05.009","article-title":"Treatment of metastatic colorectal cancer","volume":"38","author":"Davies","year":"2011","journal-title":"Semin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/1758834015572343","article-title":"Therapeutic strategy in unresectable metastatic colorectal cancer: An updated review","volume":"7","author":"Chibaudel","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wu, C.-P., Hung, T.-H., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y.-T., Wang, S.-P., and Wu, Y.-S. (2020). Erdafitinib Re-sensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic An-ticancer Drugs. Cancers, 12.","DOI":"10.3390\/cancers12061366"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Ryu, H., Ock, C.-Y., Suh, K.J., Lee, J.Y., Kim, J.-W., Lee, J.-O., Kim, J.W., Kim, Y.J., and Lee, K.-W. (2018). BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103164"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13848","DOI":"10.3390\/molecules190913848","article-title":"Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance","volume":"19","author":"Anreddy","year":"2014","journal-title":"Molecules"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multi-drug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-018-0775-3","article-title":"Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:35:30Z","timestamp":1790224530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":85,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193074"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193074","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}